Bundelkhand Online Journal

Primary Hyperoxaluria Market to Witness Growth by 2032, Estimates DelveInsight | Companies- Oxthera, Allena Pharmaceuticals, Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals

 Breaking News
  • No posts were found

Primary Hyperoxaluria Market to Witness Growth by 2032, Estimates DelveInsight | Companies- Oxthera, Allena Pharmaceuticals, Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals

March 21
03:40 2023
Primary Hyperoxaluria Market to Witness Growth by 2032, Estimates DelveInsight | Companies- Oxthera, Allena Pharmaceuticals, Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals
Primary Hyperoxaluria Market

DelveInsight’s “Primary Hyperoxaluria Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Primary Hyperoxaluria, historical and forecasted epidemiology as well as the Primary Hyperoxaluria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Primary Hyperoxaluria market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Primary Hyperoxaluria market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Primary Hyperoxaluria treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Primary Hyperoxaluria market.

 

Request for a Free Sample Report @ Primary Hyperoxaluria Market Insight

 

Some facts of Primary Hyperoxaluria market report are:

  • The total Primary Hyperoxaluria prevalent population in 7MM was 11,918 in 2020. Moreover, DelveInsight estimates that the Primary Hyperoxaluria prevalence is anticipated to increase by 2032. 
  • Male accounts for the maximum number of diagnosed prevalent cases as compared to females. 
  • The United States occupies the largest Primary Hyperoxaluria market share in the 7MM, with the market size worth USD 16 million in 2020.
  • Japan accounted for the smallest Primary Hyperoxaluria market share of the 7MM Primary Hyperoxaluria market.
  • Key Primary Hyperoxaluria Pipeline Therapies: Oxabact, Nedosiran (DCR-PHXC), ALLN-177, Stiripentol (Biocodex), and others.
  • Key Primary Hyperoxaluria Companies: Oxthera, Allena Pharmaceuticals, Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, and others.

 

Primary Hyperoxaluria Overview

Primary Hyperoxaluria (PH) is a rare genetic disorder caused by deficiencies in glyoxylate metabolism leading to oxalate deposition primarily in kidneys causing end-stage renal disease. It is an inherited autosomal recessive disorder and can be of three types based on the different responsible genes: type 1 (AGXT) (PH-I), type 2 (GRHPR) (PH-II), and type 3 (HOGA1) (PH-III). Signs and symptoms may include recurrent kidney stones, hematuria, and urinary tract infections (UTIs).

 

Learn more about Primary Hyperoxaluria, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/primary-hyperoxaluria-market

 

Primary Hyperoxaluria Market 

The Primary Hyperoxaluria market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Primary Hyperoxaluria market trends by analyzing the impact of current Primary Hyperoxaluria therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Primary Hyperoxaluria market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Primary Hyperoxaluria market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Primary Hyperoxaluria market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Primary Hyperoxaluria Epidemiology 

The Primary Hyperoxaluria epidemiology section provides insights into the historical and current Primary Hyperoxaluria patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Primary Hyperoxaluria market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Primary Hyperoxaluria Epidemiology Segmentation:

  • Primary Hyperoxaluria Prevalent Cases
  • Diagnosed Primary Hyperoxaluria Prevalent Cases 
  • Gender-specific Primary Hyperoxaluria Diagnosed Prevalent Cases
  • Age-specific Diagnosed Primary Hyperoxaluria Prevalent Cases 
  • Type-specific Diagnosed Primary Hyperoxaluria Prevalent Cases 

 

Explore more about Primary Hyperoxaluria Epidemiology @ https://www.delveinsight.com/sample-request/primary-hyperoxaluria-market

 

Primary Hyperoxaluria Drugs Uptake

This section focuses on the uptake rate of the potential Primary Hyperoxaluria drugs recently launched in the Primary Hyperoxaluria market or expected to be launched in 2019-2032. The analysis covers the Primary Hyperoxaluria market uptake by drugs, patient uptake by therapies, and sales of each drug.   

 

Primary Hyperoxaluria Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Primary Hyperoxaluria market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Primary Hyperoxaluria Pipeline Development Activities

The Primary Hyperoxaluria report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Primary Hyperoxaluria key players involved in developing targeted therapeutics.

 

Request for a sample report to understand more about the Primary Hyperoxaluria pipeline development activities @ https://www.delveinsight.com/sample-request/primary-hyperoxaluria-market

 

Primary Hyperoxaluria Therapeutics Assessment

Major key companies are working proactively in the Primary Hyperoxaluria Therapeutics market to develop novel therapies which will drive the Primary Hyperoxaluria treatment markets in the upcoming years are Oxthera, Allena Pharmaceuticals, Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, and others. 

 

Primary Hyperoxaluria Report Key Insights

1. Primary Hyperoxaluria Patient Population

2. Primary Hyperoxaluria Market Size and Trends

3. Key Cross Competition in the Primary Hyperoxaluria Market

4. Primary Hyperoxaluria Market Dynamics (Key Drivers and Barriers)

5. Primary Hyperoxaluria Market Opportunities

6. Primary Hyperoxaluria Therapeutic Approaches

7. Primary Hyperoxaluria Pipeline Analysis

8. Primary Hyperoxaluria Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Primary Hyperoxaluria Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Primary Hyperoxaluria Competitive Intelligence Analysis

4. Primary Hyperoxaluria Market Overview at a Glance

5. Primary Hyperoxaluria Disease Background and Overview

6. Primary Hyperoxaluria Patient Journey

7. Primary Hyperoxaluria Epidemiology and Patient Population

8. Primary Hyperoxaluria Treatment Algorithm, Current Treatment, and Medical Practices

9. Primary Hyperoxaluria Unmet Needs

10. Key Endpoints of Primary Hyperoxaluria Treatment

11. Primary Hyperoxaluria Marketed Products

12. Primary Hyperoxaluria Emerging Therapies

13. Primary Hyperoxaluria Seven Major Market Analysis

14. Attribute Analysis

15. Primary Hyperoxaluria Market Outlook (7 major markets)

16. Primary Hyperoxaluria Access and Reimbursement Overview

17. KOL Views on the Primary Hyperoxaluria Market

18. Primary Hyperoxaluria Market Drivers

19. Primary Hyperoxaluria Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

  

Trending Report:

Non-muscle Invasive Bladder Cancer Market

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting